Table of Contents
Understand the CDSCO requirements for Importing Biological products into India, including Form 10 licensing, Form 41 registration, New Drug permission under CT-19/CT-20, essential documents, fees and timelines.
Importing Biological products into India involves more than arranging shipments from overseas manufacturers. Companies must first complete the required regulatory formalities and obtain permission from the Central Drugs Standard Control Organisation (CDSCO).
Whether the product is a vaccine, blood product, recombinant DNA product or stem cell, understanding the Biological Import License India process is essential to avoid regulatory complications and import delays.
An important requirement that importers should not overlook is new drug permission. Under the New Drugs and Clinical Trials Rules, 2019, specified biological products are always deemed to be new drugs. Therefore, obtaining the applicable permission in Form CT-19 or CT-20 is an additional regulatory requirement before proceeding with the import licence application.
Under the Drugs and Cosmetics Rules, 1945, specified Biological Products require an import licence before commercial import into India.
The process involves three important regulatory stages: registration of the foreign manufacturing site and product, obtaining new drug permission, and securing the final import licence.
The relevant forms serve different purposes:
Obtaining Form 41 does not automatically permit commercial imports. The importer must complete the separate Form 10 licensing process.
Before starting the application, companies should check their eligibility. Applicants must hold the appropriate licence under the Drugs and Cosmetics Rules.
Eligible applicants generally include:
The applicant’s business details and licence information should remain consistent across all submitted documents.
Once the required Registration Certificate is available, the importer can proceed with the application.
Incomplete documentation is a common reason for regulatory queries. Preparing the required documents beforehand can make the application process smoother.
| Document | Purpose |
| Registration Certificate (Form 41) | Confirms site and product registration |
| New Drug Permission (CT-19/CT-20) | Establishes CDSCO permission to import the applicable biological product as a new drug |
| Wholesale Licence | Establishes importer eligibility |
| Manufacturing Licence | Required for eligible manufacturer applicants |
| Form 9 | Manufacturer’s or authorised agent’s undertaking |
| Product Labels | Demonstrates Indian labelling compliance |
| Covering Letter | Provides application details |
Table 1
Vaccine imports need particular attention because these products have specific storage, handling and quality requirements.
Importers should check that product labels comply with Rule 96 of the Drugs and Cosmetics Rules, 1945. They should also ensure that:
Addressing these requirements before shipment can help prevent avoidable import-related complications.
Form 10 Approval Timeline, Fees and Validity
Importers should consider the applicable fees and processing time while planning their regulatory submissions.
| Particular | Details |
| New drug application | Form CT-18 |
| New drug permission | Form CT-19 or CT-20, as applicable |
| Application form | Form 8 |
| Final licence | Form 10 |
| Government fee | ₹10,000 for one product |
| Additional product fee | ₹1,000 per product |
| Indicative processing time | 45 days |
| Licence validity | Three years or until Form 41 expires, whichever is earlier |
Table 2
The 45-day period should be treated as indicative rather than guaranteed. Incomplete applications and additional regulatory queries may extend the process.

Figure 1
Obtaining an import licence becomes easier when companies understand the regulatory sequence and prepare their documents in advance.
Understanding the Biological Import License India requirements helps manufacturers and importers plan their submissions, minimise documentation-related delays and bring biological products into the Indian market through the appropriate CDSCO pathway.
What a Revised Schedule M raises GMP standards in India, what has changed for manufacturers, and how large firms and MSMEs can prepare for Compliance and CDSCO inspections. Revised Schedule M is the b..
A practical comparison of CDSCO vs FDA vs EMA, explaining how each regulator’s Drug approval process differs and why one Drug needs separate approvals in India, the US and Europe. A Drug approve..